再鼎醫藥(09688.HK)低開一成 次季收入增幅遜預期
再鼎醫藥(09688.HK)今早(8日)低開10%,報27.34元,市前成交95.81萬股,涉資2,619.34萬元。再鼎醫藥ADR(ZALB.US)隔晚(7日)急挫12%,報34.08美元。
集團上日收市後公布6月底止中期業績,按國際財務報告準則,總收入2.17億美元,按年升15.4%。虧損淨額由對上財年同期的近1.34億美元,收窄至8,916.5萬美元,每股虧損8美仙。
單計第二季度,總收入1.1億美元,增加9%,但遜市場預期的近1.25億美元。虧損淨額由對上財年同期的8,027.7萬美元收窄至4,072.7萬美元,每股虧損4美仙,遠勝市場預期每股虧損41美仙。調整後經營虧損收窄37.3%至3,418.7萬美元,穩步邁向2025年第四季度實現盈利的目標。
公司重申了2025年5.6億至5.90億美元的全年收入指引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.